Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | HMP-2 protein | 0.0055 | 0.0031 | 0.5 |
Echinococcus multilocularis | beta catenin | 0.0055 | 0.0031 | 0.5 |
Onchocerca volvulus | Cirhin homolog | 0.0055 | 0 | 0.5 |
Brugia malayi | Armadillo/beta-catenin-like repeat family protein | 0.0055 | 0.0031 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0135 | 0.6851 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Log PI (functional) | = 0 | Log value of the protective index was calculated | ChEMBL. | 2299649 |
Log PI (functional) | = 0 | Log value of the protective index was calculated | ChEMBL. | 2299649 |
No. of Colony forming Units (functional) | = 5.67 | No of CFU was determined that cause 50% lethality against P. aeruginosa after 40 mg/kg sc administration | ChEMBL. | 2299649 |
No. of Colony forming Units (functional) | = 7.5 | No of CFU was determined that cause 50% lethality against P. aeruginosa after 40 mg/kg sc administration | ChEMBL. | 2299649 |
No. of Colony forming Units (functional) | = 56.7 | No of CFU was determined that cause 50% lethality against P. aeruginosa after 40 mg/kg sc administration | ChEMBL. | 2299649 |
No. of Colony forming Units (functional) | = 75 | No of CFU was determined that cause 50% lethality against P. aeruginosa after 40 mg/kg sc administration | ChEMBL. | 2299649 |
PI (functional) | = 0.53 | Protective index against Pseudomonas aeruginosa after 40 mg/kg subcutaneous administration pretreated 250 mg/kg cytoxan intraperitoneal on day -4. | ChEMBL. | 2299649 |
PI (functional) | = 0.7 | Protective index against Pseudomonas aeruginosa after 40 mg/kg subcutaneous administration pretreated 250 mg/kg cytoxan intraperitoneal on day -4. | ChEMBL. | 2299649 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.